Edrecolomab

Drug Profile

Edrecolomab

Alternative Names: 1083 17-1A; 17-1A; Adjuqual; C-1; CO17-1A; M-17-1A; Monoclonal antibody 17-1A; Panorex

Latest Information Update: 11 May 2006

Price : $50

At a glance

  • Originator Centocor
  • Developer Ajinomoto; Centocor
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Epithelial cell adhesion molecule inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Market Withdrawal Colorectal cancer
  • No development reported Adenocarcinoma
  • Discontinued Pancreatic cancer

Most Recent Events

  • 20 Feb 2006 No development reported - Clinical-Phase-Unknown for Adenocarcinoma in USA (IV-infusion)
  • 20 Feb 2006 Discontinued - Phase-II for Colorectal cancer in Japan (IV-infusion)
  • 07 Oct 2003 Clinical trials in Adenocarcinoma in USA (IV-infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top